70860 Federal Register / Vol. 70, No.
225 / Wednesday, November 23, 2005 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Child Health and
Human Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel, Reproductive Health
in Developing Countries P01 Review.
Date: December 5, 2005.
Time: 8:30 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Mayflower Hotel, 1127
Connecticut Avenue, NW., Washington, DC
20036.
Contact Person: Carla T. Walls, PhD,
Scientific Review Administrator, Division of
Scientific Review, National Institute of Child
Health and Human Development, NIH, 6100
Executive Blvd., Room 5B01, Bethesda, MD
20892, 301–435–6898, wallsc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: November 8, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–23201 Filed 11–22–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
VerDate Aug<31>2005 17:33 Nov 22, 2005 Jkt 208001
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Eukaryotic
Pathogens and Vectors.
Date: November 21, 2005.
Time: 8 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Crystal City Marriott, 1999 Jefferson
Davis Highway, Arlington, VA 22202.
Contact Person: Fouad A. El-Zaatari, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3206,
MSC 7808, Bethesda, MD 20814–9692. (301)
435–1149. elzaataf@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Bioengineering Technology and Surgical
Sciences.
Date: November 21, 2005.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call).
Contact Person: Roberto J. Matus, MD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7854, Bethesda, MD 20892. (301) 435–
2204. matusr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Metalloprotein Structure.
Date: November 21, 2005.
Time: 4 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Watergate, 2650 Virginia
Avenue, NW., Washington, DC 20037.
Contact Person: George W. Chacko, PhD,
Scientific Review Administrator, Center For
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4186,
MSC 7849, Bethesda, MD 20892. (301) 435–
1220. chackoge@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 E:\FR\FM\23NON1.SGM
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 8, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–23202 Filed 11–22–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Center for Substance Abuse
Prevention; Notice of Meeting
Pursuant to Pub. L. 92–463, notice is
hereby given of the meeting of the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
Drug Testing Advisory Board on
December 13–14, 2005.
A portion of the meeting will be open
and will include a roll call, general
announcements, a Department of Health
and Human Services drug testing
program update, a Department of
Transportation drug testing program
update, and a Nuclear Regulatory
Commission drug testing program
update.
Attendance by the public will be
limited to space available. Public
comments are welcome. Please
communicate with the individual listed
below as contact to make arrangements
to comment or to request special
accommodations for persons with
disabilities.
The Board will also meet to develop
the final revisions to the proposed
Mandatory Guidelines for Federal
Workplace Drug Testing Programs that
were published in the Federal Register
on April 13, 2004 (69 FR 19673) and to
discuss Federal agency specimen
results, medical review officer
interpretations, laboratory inspection
issues, and analytical instrumentation
issues. This meeting will be conducted
in closed session since discussing these
issues in open session will significantly
frustrate the Department’s ability to
develop the revisions to the Mandatory
Guidelines or to disclose information of
a personal nature where disclosure
would constitute an unwarranted
invasion of personal privacy. The HHS
Office of General Counsel made the
determination that such matters are
protected by exemptions (6) and 9(B) of
section 552b(c) of title 5 U.S.C. and
therefore may be closed to the public.
To facilitate entering the building for
the open session, public attendees are
23NON1